NBRV logo

Nabriva Therapeutics (NBRV) EBIT

Annual EBIT

-$54.92 M
-$6.86 M-14.27%

December 31, 2022

Summary

Performance

1-Year Change

-14.27%

3-Year Change

+30.91%

5-Year Change

+24.73%

15-Year Change

+24.73%

NBRV EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$22.10 M
NBRV annual earnings before interest & taxes is currently -348.52% below its historical high of $22.10 million

3-Year Low

-$54.92 M
NBRV annual earnings before interest & taxes is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
NBRV previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
NBRV next annual earnings announcement has not yet been scheduled

OtherNBRVprofitabilitymetrics:

Annual Revenue

$35.67 M
NBRV annual revenue is $35.67 million

Annual Net Income

-$57.19 M
NBRV annual net profit is -$57.19 million

Annual EBITDA

-$54.70 M
NBRV annual EBITDA is -$54.70 million

Annual EPS

-$21.32
NBRV annual earnings per share is -$21.32

Quarterly EBIT

-$8.51 M
+$13.82 M+61.91%

March 31, 2023

Summary

Performance

3-Month Change

+61.91%

1-Year Change

+24.39%

3-Year Change

+61.48%

5-Year Change

+33.71%

NBRV Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$3.73 M
NBRV quarterly earnings before interest & taxes is currently -327.92% below its historical high of $3.73 million

3-Year Low

-$22.33 M

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2023
NBRV previous earnings announcement was published on Mar 31, 2023

Next Quarterly Earnings Report Date

N/A
NBRV next earnings announcement has not yet been scheduled

OtherNBRVprofitabilitymetrics:

Quarterly Revenue

$7.59 M
NBRV quarterly revenue is $7.59 million

Quarterly Net Income

-$8.70 M
NBRV quarterly net profit is -$8.70 million

Quarterly EBITDA

-$8.48 M
NBRV quarterly EBITDA is -$8.48 million

Quarterly EPS

-$2.72
NBRV quarterly earnings per share is -$2.72

TTM EBIT

-$52.17 M
+$2.74 M+5.00%

March 31, 2023

Summary

Performance

3-Month Change

+5%

1-Year Change

-14.07%

3-Year Change

+36.69%

5-Year Change

+34.36%

NBRV TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$2.00 M

3-Year Low

-$54.92 M

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2023
NBRV previous earnings announcement was published on Mar 31, 2023

Next Quarterly Earnings Report Date

N/A
NBRV next earnings announcement has not yet been scheduled

OtherNBRVprofitabilitymetrics:

TTM Revenue

$35.59 M
NBRV TTM revenue is $35.59 million

TTM Net Income

-$54.07 M
NBRV TTM net profit is -$54.07 million

TTM EBITDA

-$52.02 M
NBRV TTM EBITDA is -$52.02 million

TTM EPS

-$19.20
NBRV TTM earnings per share is -$19.20

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

Annual EBIT

-$54.92 M
NBRV annual earnings before interest & taxes is -$54.92 million

Annual Revenue

$35.67 M
NBRV annual revenue is $35.67 million

Annual Cost Of Goods Sold

$28.58 M
NBRV annual cost of goods sold is $28.58 million

Annual Operating Expenses

$58.26 M
NBRV annual total operating expenses is $58.26 million

NBRV EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-14.3%+24.4%-14.1%
3 y3 years+30.9%+61.5%+36.7%
5 y5 years+24.7%+33.7%+34.4%

NBRV EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+14.3%at lowat high+162.5%+15.1%+5.3%
5 y5-year+14.3%+44.7%at high+162.9%+15.1%+57.9%
alltimeall time-348.5%+108.7%-327.9%+522.7%+2505.5%+137.6%

Nabriva Therapeutics EBIT History

DateAnnualQuarterlyTTM
Mar 2023
-
-$8.51 M(-61.9%)
-$52.17 M(-5.0%)
Dec 2022
-$54.92 M(+14.3%)
-$22.33 M(+105.8%)
-$54.92 M(+20.7%)
Sep 2022
-
-$10.85 M(+3.4%)
-$45.48 M(+0.4%)
Jun 2022
-
-$10.49 M(-6.7%)
-$45.32 M(-0.9%)
Mar 2022
-
-$11.25 M(-12.8%)
-$45.74 M(-4.8%)
Dec 2021
-$48.06 M(-29.0%)
-$12.89 M(+20.7%)
-$48.06 M(-9.1%)
Sep 2021
-
-$10.68 M(-2.1%)
-$52.86 M(-3.8%)
Jun 2021
-
-$10.91 M(-19.6%)
-$54.94 M(-7.0%)
Mar 2021
-
-$13.57 M(-23.3%)
-$59.10 M(-12.6%)
Dec 2020
-$67.70 M(-14.8%)
-$17.70 M(+38.6%)
-$67.62 M(-6.5%)
Sep 2020
-
-$12.77 M(-15.3%)
-$72.28 M(-5.7%)
Jun 2020
-
-$15.07 M(-31.8%)
-$76.63 M(-7.0%)
Mar 2020
-
-$22.08 M(-1.2%)
-$82.41 M(+3.7%)
Dec 2019
-$79.49 M(-30.6%)
-$22.36 M(+30.7%)
-$79.49 M(-9.8%)
Sep 2019
-
-$17.11 M(-17.9%)
-$88.10 M(-28.9%)
Jun 2019
-
-$20.85 M(+8.8%)
-$123.95 M(+2.5%)
Mar 2019
-
-$19.16 M(-38.1%)
-$120.93 M(+5.5%)
Dec 2018
-$114.60 M
-$30.97 M(-41.5%)
-$114.60 M(+8.3%)
Sep 2018
-
-$52.97 M(+197.1%)
-$105.79 M(+44.6%)
DateAnnualQuarterlyTTM
Jun 2018
-
-$17.83 M(+38.9%)
-$73.18 M(+3.2%)
Mar 2018
-
-$12.83 M(-42.1%)
-$70.92 M(-2.8%)
Dec 2017
-$72.96 M(+31.5%)
-$22.16 M(+8.9%)
-$72.96 M(+9.5%)
Sep 2017
-
-$20.36 M(+30.8%)
-$66.61 M(+10.7%)
Jun 2017
-
-$15.57 M(+4.7%)
-$60.19 M(+6.1%)
Mar 2017
-
-$14.87 M(-6.0%)
-$56.74 M(+2.3%)
Dec 2016
-$55.49 M(+119.2%)
-$15.82 M(+13.5%)
-$55.49 M(+24.2%)
Sep 2016
-
-$13.94 M(+15.0%)
-$44.67 M(+14.5%)
Jun 2016
-
-$12.12 M(-11.0%)
-$39.01 M(+20.4%)
Mar 2016
-
-$13.62 M(+172.3%)
-$32.40 M(+115.2%)
Dec 2015
-$25.32 M(+125.7%)
-$5.00 M(-39.6%)
-$15.05 M(-10.2%)
Sep 2015
-
-$8.28 M(+50.3%)
-$16.77 M(+59.6%)
Jun 2015
-
-$5.51 M(-247.6%)
-$10.51 M(+91.6%)
Mar 2015
-
$3.73 M(-155.6%)
-$5.48 M(-51.1%)
Dec 2014
-$11.22 M(-150.8%)
-$6.72 M(+232.8%)
-$11.22 M(+149.2%)
Sep 2014
-
-$2.02 M(+318.7%)
-$4.50 M(+81.2%)
Jun 2014
-
-$481.90 K(-75.9%)
-$2.48 M(+24.1%)
Mar 2014
-
-$2.00 M
-$2.00 M
Dec 2013
$22.10 M
-
-

FAQ

  • What is Nabriva Therapeutics annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Nabriva Therapeutics?
  • What is Nabriva Therapeutics annual EBIT year-on-year change?
  • What is Nabriva Therapeutics quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Nabriva Therapeutics?
  • What is Nabriva Therapeutics quarterly EBIT year-on-year change?
  • What is Nabriva Therapeutics TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Nabriva Therapeutics?
  • What is Nabriva Therapeutics TTM EBIT year-on-year change?

What is Nabriva Therapeutics annual earnings before interest & taxes?

The current annual EBIT of NBRV is -$54.92 M

What is the all time high annual EBIT for Nabriva Therapeutics?

Nabriva Therapeutics all-time high annual earnings before interest & taxes is $22.10 M

What is Nabriva Therapeutics annual EBIT year-on-year change?

Over the past year, NBRV annual earnings before interest & taxes has changed by -$6.86 M (-14.27%)

What is Nabriva Therapeutics quarterly earnings before interest & taxes?

The current quarterly EBIT of NBRV is -$8.51 M

What is the all time high quarterly EBIT for Nabriva Therapeutics?

Nabriva Therapeutics all-time high quarterly earnings before interest & taxes is $3.73 M

What is Nabriva Therapeutics quarterly EBIT year-on-year change?

Over the past year, NBRV quarterly earnings before interest & taxes has changed by +$2.74 M (+24.39%)

What is Nabriva Therapeutics TTM earnings before interest & taxes?

The current TTM EBIT of NBRV is -$52.17 M

What is the all time high TTM EBIT for Nabriva Therapeutics?

Nabriva Therapeutics all-time high TTM earnings before interest & taxes is -$2.00 M

What is Nabriva Therapeutics TTM EBIT year-on-year change?

Over the past year, NBRV TTM earnings before interest & taxes has changed by -$6.44 M (-14.07%)